RBC keeps Pharmacyclics at sector perform

Pharmacyclics, Inc. was maintained by RBC Capital Markets analyst David Bouchey at sector perform, speculative risk after the company presented analysis of phase 3 data supporting its New Drug Application for Xcytrin. While the trial did not statistically meet its primary endpoint of delaying time to neurologic progression on an intent-to-treat basis, a sizable effect was seen, according to the analyst. Shares of the Sunnydale, Calif.-based pharmaceutical company were up 6 cents, or 1.25%, at $4.85 on volume of 67,442 shares versus the three-month running average of 122,502 shares. (Nasdaq: PCYC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.